Cargando…
A prospective, open-label, single arm, multicentre study to evaluate efficacy, safety and acceptability of pericoital oral contraception using levonorgestrel 1.5 mg
STUDY QUESTION: Will the use of levonorgestrel (LNG) 1.5 mg taken at each day of coitus by women who have relatively infrequent sex be an efficacious, safe and acceptable contraceptive method? SUMMARY ANSWER: Typical use of LNG 1.5 mg taken pericoitally, before or within 24 h of sexual intercourse,...
Autores principales: | Festin, Mario P.R., Bahamondes, Luis, Nguyen, Thi My Huong, Habib, Ndema, Thamkhantho, Manopchai, Singh, Kuldip, Gosavi, Arundhati, Bartfai, Gyorgy, Bito, Tamas, Bahamondes, M. Valeria, Kapp, Nathalie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755445/ https://www.ncbi.nlm.nih.gov/pubmed/26830816 http://dx.doi.org/10.1093/humrep/dev341 |
Ejemplares similares
-
Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant
por: Ali, Moazzam, et al.
Publicado: (2016) -
Weight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception did not influence early discontinuation
por: Bahamondes, Luis
Publicado: (2021) -
Extended Effectiveness of the Etonogestrel-Releasing Contraceptive Implant and the 20 µg Levonorgestrel-Releasing Intrauterine System for 2 Years Beyond U.S. Food and Drug Administration Product Labeling
por: Ali, Moazzam, et al.
Publicado: (2017) -
Feasibility of e-commerce pharmacy provision and acceptability of levonorgestrel 1.5 mg for pericoital use in urban and peri-urban settings in Kenya: a prospective cohort study
por: Odwe, George, et al.
Publicado: (2023) -
New and emerging contraceptives: a state-of-the-art review
por: Bahamondes, Luis, et al.
Publicado: (2014)